Moderate-to-Severe Atopic Dermatitis research hub

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

This study is looking at a new medicine called nemolizumab for people with moderate to severe eczema. It aims to understand how safe and effective the medicine is over a long period. Participants would have been in a previous nemolizumab study.

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

This study is testing a new oral medication, SYX-5219, for moderate to severe eczema (atopic dermatitis). It aims to check the drug's safety, how well it's tolerated, and how it moves through the body in both healthy people and those with eczema.

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis

This study is testing a new medicine, JNJ-95475939, for adults who have moderate to severe eczema (atopic dermatitis). Researchers want to see if it helps improve skin symptoms compared to a dummy medicine or an existing treatment called Dupixent.

A Phase IV, non-randomized, open-label multinational trial to assess the mechanism of action for Lebrikizumab in moderate-to-severe atopic dermatitis

This study looks at how a new medicine, Ebglyss, works for people with moderate to severe eczema. Researchers will examine changes in skin samples over time to understand its effects at a very detailed level.

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis

B7451015 - A PHASE 3 MULTICENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS